Latest Period
Q1 2026
Security Snapshot
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) Institutional Ownership
CUSIP: 492327101
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
146
Shares (Excl. Options)
18,564,107
Price
$11.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- KROS on Nasdaq
- Shares outstanding
- 19,716,217
- Price per share
- $12.55
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 18,564,107
- Total reported value
- $204,928,901
- % of total 13F portfolios
- 0%
- Share change
- -1,605,604
- Value change
- -$29,235,654
- Number of holders
- 146
- Price from insider filings
- $12.55
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 492327101.
- 146 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 161 to 146 between Q4 2025 and Q1 2026.
- Reported value moved from $408,413,646 to $204,928,901.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 146 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 492327101?
CUSIP 492327101 identifies KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 492327101:
Significant Owners of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | $21,971,928 | 1,990,842 | BlackRock, Inc. | 31 Mar 2026 | |||
| Nantahala Capital Management, LLC | 6.9% | $17,073,258 | 1,360,419 | Nantahala Capital Management, LLC | 31 Mar 2026 | |||
| ALKEON CAPITAL MANAGEMENT LLC | 2.7% | $15,645,210 | 1,101,000 | Alkeon Capital Management LLC | 31 Dec 2024 | |||
| Madison Avenue Partners, LP | 2.7% | -62% | $16,062,286 | -$34,918,552 | 823,707 | -68% | Madison Avenue International LP | 31 Dec 2025 |
| D. E. SHAW & CO, L.P. | 3.9% | -24% | $14,745,042 | -$15,400,944 | 756,156 | -51% | D. E. Shaw & Co., L.P. | 31 Dec 2025 |
| FMR LLC | 1.7% | $10,010,547 | 704,472 | FMR LLC | 31 Jan 2025 | |||
| JPMORGAN CHASE & CO | 0.2% | -102% | $1,617,141 | -$35,146,204 | 113,803 | -96% | JPMORGAN CHASE & CO. | 30 Apr 2025 |
| ExodusPoint Capital Management, LP | 0.04% | -104% | $260,520 | -$36,943,510 | 13,360 | -99% | ExodusPoint Capital Management, LP | 31 Dec 2025 |
As of 31 Mar 2026, 146 institutional investors reported holding 18,564,107 shares of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS). This represents 94% of the company’s total 19,716,217 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) together control 75% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 2,411,793 | +5.3% | 0% | $26,626,189 |
| Nantahala Capital Management, LLC | 6.9% | 1,360,419 | +277% | 0.94% | $15,019,026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 831,421 | 0% | 0% | $9,178,888 |
| ORBIMED ADVISORS LLC | 3.9% | 759,155 | -5.6% | 0.19% | $8,381,071 |
| Qube Research & Technologies Ltd | 3.7% | 724,926 | -7.5% | 0.01% | $8,003,183 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3.6% | 706,071 | -8.1% | 0.03% | $7,795,024 |
| FEDERATED HERMES, INC. | 3.5% | 689,229 | +5.3% | 0.01% | $7,609,089 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 682,043 | 0% | 0% | $7,529,755 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5% | 681,460 | +7.3% | 0% | $7,524,833 |
| Madison Avenue Partners, LP | 3.2% | 626,583 | -24% | 0.3% | $6,917,476 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3% | 590,249 | -56% | 0% | $6,516,349 |
| STATE STREET CORP | 2.8% | 561,730 | -48% | 0% | $6,201,499 |
| D. E. Shaw & Co., Inc. | 2.6% | 509,608 | -33% | 0% | $5,626,072 |
| RENAISSANCE TECHNOLOGIES LLC | 2.3% | 453,482 | -23% | 0.01% | $5,006,441 |
| CITADEL ADVISORS LLC | 2.1% | 406,666 | -14% | 0% | $4,489,592 |
| AQR CAPITAL MANAGEMENT LLC | 2.1% | 406,563 | +125% | 0% | $4,488,455 |
| TWO SIGMA INVESTMENTS, LP | 1.8% | 363,835 | +14% | 0% | $4,016,738 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 321,360 | +454% | 0% | $3,547,031 |
| Nuveen, LLC | 1.3% | 262,075 | +315% | 0% | $2,893,308 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.3% | 257,884 | -20% | 0.01% | $2,847,039 |
| NORTHERN TRUST CORP | 1.3% | 254,187 | +1.4% | 0% | $2,806,224 |
| Man Group plc | 1.2% | 238,618 | +25% | 0.01% | $2,634,343 |
| GOLDMAN SACHS GROUP INC | 1.1% | 224,479 | -62% | 0% | $2,478,248 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.99% | 195,017 | +225% | 0.04% | $2,152,988 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.91% | 179,952 | -3.7% | 0% | $1,986,670 |
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 18,564,107 | $204,928,901 | -$29,235,654 | $11.04 | 146 |
| 2025 Q4 | 20,068,368 | $408,413,646 | -$274,881,622 | $20.36 | 161 |
| 2025 Q3 | 35,272,212 | $558,014,186 | -$7,638,925 | $15.82 | 151 |
| 2025 Q2 | 35,922,272 | $479,567,957 | +$53,894,426 | $13.35 | 134 |
| 2025 Q1 | 32,796,190 | $334,208,916 | -$101,548,195 | $10.19 | 154 |
| 2024 Q4 | 36,741,918 | $581,640,265 | -$99,583,348 | $15.83 | 159 |
| 2024 Q3 | 34,948,467 | $2,029,993,469 | +$197,656,348 | $58.07 | 162 |
| 2024 Q2 | 31,483,081 | $1,437,735,495 | -$1,704,535 | $45.70 | 150 |
| 2024 Q1 | 31,378,208 | $2,077,197,760 | +$376,189,592 | $66.20 | 144 |
| 2023 Q4 | 25,748,679 | $1,023,986,857 | +$107,389,201 | $39.76 | 119 |
| 2023 Q3 | 22,915,590 | $730,562,303 | +$10,983,703 | $31.88 | 106 |
| 2023 Q2 | 22,423,232 | $900,980,099 | +$13,493,306 | $40.18 | 121 |
| 2023 Q1 | 22,003,238 | $936,983,921 | +$94,494,039 | $42.70 | 128 |
| 2022 Q4 | 19,814,952 | $951,517,038 | +$88,887,412 | $48.02 | 122 |
| 2022 Q3 | 18,166,429 | $683,394,048 | +$33,259,877 | $37.62 | 107 |
| 2022 Q2 | 17,360,328 | $479,673,115 | +$10,253,619 | $27.63 | 101 |
| 2022 Q1 | 16,425,972 | $892,979,574 | +$13,785,386 | $54.38 | 101 |
| 2021 Q4 | 16,155,340 | $944,400,680 | +$68,408,989 | $58.51 | 96 |
| 2021 Q3 | 13,732,777 | $543,300,250 | -$15,835,150 | $39.56 | 86 |
| 2021 Q2 | 14,120,390 | $599,680,759 | -$43,588,395 | $42.47 | 79 |
| 2021 Q1 | 14,412,080 | $887,014,019 | -$122,639,102 | $61.55 | 83 |
| 2020 Q4 | 16,029,747 | $1,129,296,879 | +$301,336,670 | $70.54 | 81 |
| 2020 Q3 | 11,780,724 | $454,579,430 | +$33,779,230 | $38.57 | 49 |
| 2020 Q2 | 10,926,163 | $409,790,602 | +$409,790,602 | $37.51 | 51 |